Literature DB >> 15703950

Protein transduction technology.

Masayuki Matsushita1, Hideki Matsui.   

Abstract

With the elucidation of the human genome, exhaustive analysis of genomic data related to gene transcription and the structure and function of translated protein products has progressed rapidly. Delivery of proteins and their functional domains or inhibitory peptides directly into the cell is ideal to use this protein information and analyze associated physiological functions. Protein transduction technology, which controls cell function via direct delivery of a desired protein into the cell, involves fusing the protein with a special peptide sequence consisting of 10-20 amino acids, referred to as the protein transduction domain. The recent discovery that the protein transduction domain can also be inserted into various macromolecules heightens expectations in terms of development of novel advanced experimental tools and clinical reagents.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15703950     DOI: 10.1007/s00109-004-0633-1

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  29 in total

1.  Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans.

Authors:  M Tyagi; M Rusnati; M Presta; M Giacca
Journal:  J Biol Chem       Date:  2000-10-06       Impact factor: 5.157

2.  Photo-acceleration of protein release from endosome in the protein transduction system.

Authors:  Masayuki Matsushita; Hirofumi Noguchi; Yun-Fei Lu; Kazuhito Tomizawa; Hiroyuki Michiue; Sheng-Tian Li; Kenzo Hirose; Susan Bonner-Weir; Hideki Matsui
Journal:  FEBS Lett       Date:  2004-08-13       Impact factor: 4.124

3.  A new cell-permeable peptide allows successful allogeneic islet transplantation in mice.

Authors:  Hirofumi Noguchi; Masayuki Matsushita; Teru Okitsu; Akiyoshi Moriwaki; Kazuhito Tomizawa; Sunghyun Kang; Sheng-Tian Li; Naoya Kobayashi; Shinichi Matsumoto; Koich Tanaka; Noriaki Tanaka; Hideki Matsui
Journal:  Nat Med       Date:  2004-02-08       Impact factor: 53.440

4.  Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration.

Authors:  H Nagahara; A M Vocero-Akbani; E L Snyder; A Ho; D G Latham; N A Lissy; M Becker-Hapak; S A Ezhevsky; S F Dowdy
Journal:  Nat Med       Date:  1998-12       Impact factor: 53.440

5.  Protection against ischemic brain injury by protein therapeutics.

Authors:  Sadamitsu Asoh; Ikuroh Ohsawa; Takashi Mori; Ken-Ichiro Katsura; Tomoharu Hiraide; Yasuo Katayama; Megumi Kimura; Daiya Ozaki; Kumi Yamagata; Shigeo Ohta
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-10       Impact factor: 11.205

6.  Uptake of HIV-1 tat protein mediated by low-density lipoprotein receptor-related protein disrupts the neuronal metabolic balance of the receptor ligands.

Authors:  Y Liu; M Jones; C M Hingtgen; G Bu; N Laribee; R E Tanzi; R D Moir; A Nath; J J He
Journal:  Nat Med       Date:  2000-12       Impact factor: 53.440

7.  Protein transduction domain of HIV-1 Tat protein promotes efficient delivery of DNA into mammalian cells.

Authors:  A Eguchi; T Akuta; H Okuyama; T Senda; H Yokoi; H Inokuchi; S Fujita; T Hayakawa; K Takeda; M Hasegawa; M Nakanishi
Journal:  J Biol Chem       Date:  2001-05-09       Impact factor: 5.157

8.  In Vivo Delivery of a Bcl-xL Fusion Protein Containing the TAT Protein Transduction Domain Protects against Ischemic Brain Injury and Neuronal Apoptosis.

Authors:  Guodong Cao; Wei Pei; Hailiang Ge; Qinhua Liang; Yumin Luo; Frank R Sharp; Aigang Lu; Ruiqiong Ran; Steven H Graham; Jun Chen
Journal:  J Neurosci       Date:  2002-07-01       Impact factor: 6.167

9.  Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis.

Authors:  Jehangir S Wadia; Radu V Stan; Steven F Dowdy
Journal:  Nat Med       Date:  2004-02-08       Impact factor: 53.440

10.  Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide.

Authors:  Eric L Snyder; Bryan R Meade; Cheryl C Saenz; Steven F Dowdy
Journal:  PLoS Biol       Date:  2004-02-17       Impact factor: 8.029

View more
  6 in total

Review 1.  Therapeutic antibodies: successes, limitations and hopes for the future.

Authors:  Patrick Chames; Marc Van Regenmortel; Etienne Weiss; Daniel Baty
Journal:  Br J Pharmacol       Date:  2009-05       Impact factor: 8.739

2.  CXXC5 is a negative-feedback regulator of the Wnt/β-catenin pathway involved in osteoblast differentiation.

Authors:  H-Y Kim; J-Y Yoon; J-H Yun; K-W Cho; S-H Lee; Y-M Rhee; H-S Jung; H J Lim; H Lee; J Choi; J-N Heo; W Lee; K T No; D Min; K-Y Choi
Journal:  Cell Death Differ       Date:  2015-01-30       Impact factor: 15.828

Review 3.  Vectorology and factor delivery in induced pluripotent stem cell reprogramming.

Authors:  Kejin Hu
Journal:  Stem Cells Dev       Date:  2014-04-16       Impact factor: 3.272

4.  Cycling of CRYPTOCHROME proteins is not necessary for circadian-clock function in mammalian fibroblasts.

Authors:  Yunzhen Fan; Akiko Hida; Daniel A Anderson; Mariko Izumo; Carl Hirschie Johnson
Journal:  Curr Biol       Date:  2007-06-21       Impact factor: 10.834

5.  Expression and purification of TAT-fused carbonic anhydrase III and its effect on C2C12 cell apoptosis induced by hypoxia/reoxygenation.

Authors:  Xiliang Shang; Yuanyuan Bao; Shiyi Chen; Huimin Ren; He Huang; Yunxia Li
Journal:  Arch Med Sci       Date:  2012-09-08       Impact factor: 3.318

6.  The Dishevelled-binding protein CXXC5 negatively regulates cutaneous wound healing.

Authors:  Soung-Hoon Lee; Mi-Yeon Kim; Hyun-Yi Kim; Young-Mi Lee; Heesu Kim; Kyoung Ae Nam; Mi Ryung Roh; Do Sik Min; Kee Yang Chung; Kang-Yell Choi
Journal:  J Exp Med       Date:  2015-06-08       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.